Unlocking the promise of cell therapy via the optimized immune cell engager platform
Acepodia has designed enhanced cell therapy approaches by applying Antibody-Cell Conjugation (ACC) technology. The company's next-generation therapies are based on proprietary immune cells combined with both novel and well-established targeting mechanisms through ACC technology which is based on the 2022 Nobel Prize click chemistry from Professor Carolyn Bertozzi.
Antibody-Cell Conjugation (ACC) technology ,a family of Click Chemistry from Nobel Prize laureate- Professor Carolyn Bertozzi’s Lab binds tumor-targeting antibodies to a variety of receptors of immune cells that allows for better recognition, and can significantly enhance the potency of immune cells.
γδ2 T cells are an off-the-shelf cell line that are equipped with two independent recognition pathways to sense stressed and transformed cells (e.g., TCRs as well as activating NK receptors).
oNK cells are a unique off-the-shelf natural killer cell line, with potent anticancer activity, ideally suited for application of tumor-targeting machinery, such as through ACC technology.